GE Healthcare Technologies, Inc.

{
  "main_header": {
    "sid": 1291818,
    "name": "GE Healthcare Technologies, Inc.",
    "stock_name": "GE Healthcare Technologies, Inc.",
    "full_name": "GE Healthcare Technologies, Inc.",
    "name_url": "stocks-analysis/ge-healthcare-technologies-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "78.83",
    "chg": -3.68,
    "chgp": "-4.46%",
    "dir": -1,
    "prev_price": "82.51",
    "mcapval": "35,684.89",
    "mcap": "Mid Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US36266G1076",
    "curr_date": "Jan 20",
    "curr_time": "",
    "bse_nse_vol": "3.75 M",
    "exc_status": "Active",
    "traded_date": "Jan 20, 2026",
    "traded_date_str": "2026 01 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ge-healthcare-technologies-inc-1291818-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is GE Healthcare Technologies, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ge-healthcare-technologies-inc-overvalued-or-undervalued-3711454",
        "imagepath": "",
        "date": "2025-11-18 11:14:56",
        "description": "As of 14 November 2025, the valuation grade for GE Healthcare Technologies, Inc. moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 14, an EV to EBITDA of 11.16, and a PEG ratio of 0.39, which suggest that the stock is reasonably priced relative to its earnings growth potential.\n\nIn comparison to peers, GE Healthcare's P/E ratio of 14 is significantly lower than Edwards Lifesciences Corp.'s P/E of 31.17 and Agilent Technologies, Inc.'s P/E of 27.42, indicating a more attractive valuation relative to these companies. Additionally, while GE Healthcare has underperformed against the S&P 500 with a year-to-date return of -9.66% compared to the index's 14.49%, this may present a buying opportunity for investors looking for value in the pharmaceuticals and biotechnology sector...."
      },
      {
        "title": "Is GE Healthcare Technologies, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ge-healthcare-technologies-inc-overvalued-or-undervalued-3706982",
        "imagepath": "",
        "date": "2025-11-17 11:09:01",
        "description": "As of 14 November 2025, the valuation grade for GE Healthcare Technologies, Inc. has moved from very attractive to attractive, indicating a shift towards a more cautious outlook. The company appears to be overvalued given its current metrics, particularly when compared to its peers. The P/E ratio stands at 14, while the PEG ratio is notably low at 0.39, suggesting that the stock is priced attractively relative to its growth potential, but this is offset by a relatively high Price to Book Value of 3.57.\n\nIn comparison to peers, GE Healthcare's P/E ratio of 14 is significantly lower than that of Edwards Lifesciences Corp. at 31.17 and Agilent Technologies, Inc. at 27.42, indicating that it may be undervalued relative to these companies. However, the overall market performance shows that GE Healthcare has underperformed the S&P 500 year-to-date with a return of -6.43% compared to the index's 14.49%, reinforcin..."
      },
      {
        "title": "Is GE Healthcare Technologies, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ge-healthcare-technologies-inc-overvalued-or-undervalued-3705622",
        "imagepath": "",
        "date": "2025-11-16 11:05:40",
        "description": "As of 14 November 2025, the valuation grade for GE Healthcare Technologies, Inc. has moved from very attractive to attractive, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 14, an EV to EBITDA of 11.16, and a PEG ratio of 0.39, suggesting that the stock is reasonably priced relative to its growth prospects.\n\nIn comparison to its peers, GE Healthcare Technologies has a lower P/E ratio than Edwards Lifesciences Corp. at 31.17 and Agilent Technologies, Inc. at 27.42, indicating it may be undervalued relative to these companies. The company's recent performance shows a year-to-date return of -6.43%, while the S&P 500 has returned 14.49%, reinforcing the notion that the stock may be underperforming the broader market...."
      },
      {
        "title": "Is GE Healthcare Technologies, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ge-healthcare-technologies-inc-overvalued-or-undervalued-3689314",
        "imagepath": "",
        "date": "2025-11-11 11:35:11",
        "description": "As of 7 November 2025, the valuation grade for GE Healthcare Technologies, Inc. has moved from attractive to very attractive. The company appears to be undervalued, supported by a P/E ratio of 14, a PEG ratio of 0.39, and an EV to EBITDA ratio of 11.16, all of which suggest favorable valuation metrics compared to its peers. In comparison, Edwards Lifesciences Corp. has a significantly higher P/E ratio of 31.17, indicating it is considered expensive, while Agilent Technologies, Inc. has a fair valuation with a P/E of 27.42.\n\nDespite a challenging year with a stock return of -14.5%, which underperformed the S&P 500's return of 12.65% over the same period, the company's strong ROCE of 18.89% and ROE of 25.79% highlight its operational efficiency and profitability. Overall, these factors suggest that GE Healthcare Technologies, Inc. is positioned as an attractive investment opportunity in the current market...."
      },
      {
        "title": "Is GE Healthcare Technologies, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ge-healthcare-technologies-inc-overvalued-or-undervalued-3685119",
        "imagepath": "",
        "date": "2025-11-10 11:16:29",
        "description": "As of 7 November 2025, the valuation grade for GE Healthcare Technologies, Inc. has moved from attractive to very attractive, indicating a strong improvement in its valuation outlook. The company appears undervalued, supported by a P/E ratio of 14, a PEG ratio of 0.39, and an EV to EBITDA ratio of 11.16, which are all favorable compared to its peers. For instance, Edwards Lifesciences Corp. has a significantly higher P/E ratio of 31.17, while Agilent Technologies, Inc. shows a P/E of 27.42, suggesting that GE Healthcare is trading at a discount relative to these competitors.\n\nDespite the positive valuation metrics, GE Healthcare has underperformed relative to the S&P 500, with a year-to-date return of -6.56% compared to the index's 14.40%. This performance contrast may indicate that the market has not yet fully recognized the company's attractive valuation, reinforcing the view that it is currently underval..."
      },
      {
        "title": "Is GE Healthcare Technologies, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ge-healthcare-technologies-inc-overvalued-or-undervalued-3683218",
        "imagepath": "",
        "date": "2025-11-09 11:10:01",
        "description": "As of 7 November 2025, the valuation grade for GE Healthcare Technologies, Inc. moved from attractive to very attractive. Based on the current metrics, the company appears to be undervalued. The P/E ratio stands at 14, significantly lower than the peer average of approximately 15.07, while the EV to EBITDA ratio of 11.16 also suggests a favorable valuation compared to peers like Edwards Lifesciences Corp., which has an EV to EBITDA of 26.51. Additionally, the PEG ratio of 0.39 indicates strong growth potential relative to its price.\n\nIn comparison to its peers, GE Healthcare Technologies is positioned well with a ROE of 25.79% and a ROCE of 18.89%, reflecting efficient use of equity and capital. However, the company's recent stock performance has lagged behind the S&P 500, with a year-to-date return of -6.56% compared to the index's 14.40%. This underperformance may present a buying opportunity given the at..."
      }
    ],
    "total": 18,
    "sid": "1291818",
    "stock_news_url": "https://www.marketsmojo.com/news/ge-healthcare-technologies-inc-1291818"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is GE Healthcare Technologies, Inc. overvalued or undervalued?

2025-11-18 11:14:56

As of 14 November 2025, the valuation grade for GE Healthcare Technologies, Inc. moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 14, an EV to EBITDA of 11.16, and a PEG ratio of 0.39, which suggest that the stock is reasonably priced relative to its earnings growth potential. In comparison to peers, GE Healthcare's P/E ratio of 14 is significantly lower than Edwards Lifesciences Corp.'s P/E of 31.17 and Agilent Technologies, Inc.'s P/E of 27.42, indicating a more attractive valuation relative to these companies. Additionally, while GE Healthcare has underperformed against the S&P 500 with a year-to-date return of -9.66% compared to the index's 14.49%, this may present a buying opportunity for investors looking for value in the pharmaceuticals and biotechnology sector....

Read full news article

Is GE Healthcare Technologies, Inc. overvalued or undervalued?

2025-11-17 11:09:01

As of 14 November 2025, the valuation grade for GE Healthcare Technologies, Inc. has moved from very attractive to attractive, indicating a shift towards a more cautious outlook. The company appears to be overvalued given its current metrics, particularly when compared to its peers. The P/E ratio stands at 14, while the PEG ratio is notably low at 0.39, suggesting that the stock is priced attractively relative to its growth potential, but this is offset by a relatively high Price to Book Value of 3.57. In comparison to peers, GE Healthcare's P/E ratio of 14 is significantly lower than that of Edwards Lifesciences Corp. at 31.17 and Agilent Technologies, Inc. at 27.42, indicating that it may be undervalued relative to these companies. However, the overall market performance shows that GE Healthcare has underperformed the S&P 500 year-to-date with a return of -6.43% compared to the index's 14.49%, reinforcin...

Read full news article

Is GE Healthcare Technologies, Inc. overvalued or undervalued?

2025-11-16 11:05:40

As of 14 November 2025, the valuation grade for GE Healthcare Technologies, Inc. has moved from very attractive to attractive, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 14, an EV to EBITDA of 11.16, and a PEG ratio of 0.39, suggesting that the stock is reasonably priced relative to its growth prospects. In comparison to its peers, GE Healthcare Technologies has a lower P/E ratio than Edwards Lifesciences Corp. at 31.17 and Agilent Technologies, Inc. at 27.42, indicating it may be undervalued relative to these companies. The company's recent performance shows a year-to-date return of -6.43%, while the S&P 500 has returned 14.49%, reinforcing the notion that the stock may be underperforming the broader market....

Read full news article

Is GE Healthcare Technologies, Inc. overvalued or undervalued?

2025-11-11 11:35:11

As of 7 November 2025, the valuation grade for GE Healthcare Technologies, Inc. has moved from attractive to very attractive. The company appears to be undervalued, supported by a P/E ratio of 14, a PEG ratio of 0.39, and an EV to EBITDA ratio of 11.16, all of which suggest favorable valuation metrics compared to its peers. In comparison, Edwards Lifesciences Corp. has a significantly higher P/E ratio of 31.17, indicating it is considered expensive, while Agilent Technologies, Inc. has a fair valuation with a P/E of 27.42. Despite a challenging year with a stock return of -14.5%, which underperformed the S&P 500's return of 12.65% over the same period, the company's strong ROCE of 18.89% and ROE of 25.79% highlight its operational efficiency and profitability. Overall, these factors suggest that GE Healthcare Technologies, Inc. is positioned as an attractive investment opportunity in the current market....

Read full news article

Is GE Healthcare Technologies, Inc. overvalued or undervalued?

2025-11-10 11:16:29

As of 7 November 2025, the valuation grade for GE Healthcare Technologies, Inc. has moved from attractive to very attractive, indicating a strong improvement in its valuation outlook. The company appears undervalued, supported by a P/E ratio of 14, a PEG ratio of 0.39, and an EV to EBITDA ratio of 11.16, which are all favorable compared to its peers. For instance, Edwards Lifesciences Corp. has a significantly higher P/E ratio of 31.17, while Agilent Technologies, Inc. shows a P/E of 27.42, suggesting that GE Healthcare is trading at a discount relative to these competitors. Despite the positive valuation metrics, GE Healthcare has underperformed relative to the S&P 500, with a year-to-date return of -6.56% compared to the index's 14.40%. This performance contrast may indicate that the market has not yet fully recognized the company's attractive valuation, reinforcing the view that it is currently underval...

Read full news article

Is GE Healthcare Technologies, Inc. overvalued or undervalued?

2025-11-09 11:10:01

As of 7 November 2025, the valuation grade for GE Healthcare Technologies, Inc. moved from attractive to very attractive. Based on the current metrics, the company appears to be undervalued. The P/E ratio stands at 14, significantly lower than the peer average of approximately 15.07, while the EV to EBITDA ratio of 11.16 also suggests a favorable valuation compared to peers like Edwards Lifesciences Corp., which has an EV to EBITDA of 26.51. Additionally, the PEG ratio of 0.39 indicates strong growth potential relative to its price. In comparison to its peers, GE Healthcare Technologies is positioned well with a ROE of 25.79% and a ROCE of 18.89%, reflecting efficient use of equity and capital. However, the company's recent stock performance has lagged behind the S&P 500, with a year-to-date return of -6.56% compared to the index's 14.40%. This underperformance may present a buying opportunity given the at...

Read full news article

View All News